Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 12/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 1.00 |
| ▸ | ABL2 | P42684 | 7/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 3/20 | 1.00 |
| ▸ | LYN | P07948 | 3/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | SYK | P43405 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | DDX3X | O00571 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL29355523 | 1.00 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3827 | 1.00 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2236091 | 1.00 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL15201213 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2929858 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3138052 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL1462774 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL529425 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL1977949 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL16431247 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 908 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014129-A1 | MITOCHONDRIAL PYRUVATE METABOLISM INHIBITORS FOR TREATING CHRONIC MYELOID LEUKEMIA | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2026-01-15 | — | — | US | claimed |
| US-12522873-B2 | ALK and NTRK1 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2026-01-13 | — | — | US | claimed |
| US-20260007666-A1 | INHALABLE IMATINIB FORMULATION | INAYA THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | claimed |
| WO-2025122699-A1 | CDC7 INHIBITOR COMBINATIONAL THERAPY | Lin Bioscience, Inc. (TW) | 2025-06-12 | — | — | WO | claimed |
| EP-4554590-A1 | INHALABLE IMATINIB FORMULATION | Inaya Therapeutics, Inc. (US) | 2025-05-21 | — | — | EP | claimed |
| US-20250090495-A1 | CDC7 Inhibitor Combinational Therapy | Lin Bioscience, Inc. (TW) | 2025-03-20 | — | — | US | claimed |
| CN-119490479-A | Preparation method of imatinib mesylate | 广州科锐特药业有限公司 | 2025-02-21 | — | — | CN | claimed |
| WO-2024015518-A1 | INHALABLE IMATINIB FORMULATION | INAYA THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | claimed |
| EP-4274577-A1 | INHALABLE IMATINIB FORMULATION | InCarda Therapeutics, Inc. (US) | 2023-11-15 | — | — | EP | claimed |
| CN-116897045-A | Inhalable imatinib formulations | 英凯达治疗公司 | 2023-10-17 | — | — | CN | claimed |
| EP-3527211-B1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR REMISSION OF CHRONIC MYELOGENOUS LEUKEMIA | DELTA FLY PHARMA INC (JP) | 2023-08-23 | — | — | EP | claimed |
| CN-112125882-B | Method for synthesizing imatinib free base | 山东汇海医药化工有限公司 | 2023-04-11 | — | — | CN | claimed |
| US-20220241278-A1 | INHALABLE IMATINIB FORMULATION | INCARDA THERAPEUTICS, INC. | 2022-08-04 | — | — | US | claimed |
| WO-2022150483-A1 | INHALABLE IMATINIB FORMULATION | INCARDA THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | claimed |
| US-12637415-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | DRACEN PHARMACEUTICALS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-05-26 | — | — | US | disclosed |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-11230589-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11229650-B2 | Inhalable imatinib formulations, manufacture, and uses thereof | Aerovate Therapeutics, Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| CN-113952457-A | Application of termitimide or pharmaceutical composition containing termitimide in resisting coronavirus | 欣凯医药化工中间体（上海）有限公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230589-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | ABL1 1369/4885BCR 8/4885KIT 1784/4885 |
| US-20260007666-A1 | INHALABLE IMATINIB FORMULATION | ABL1, MCL1, BCR | ABL1 1/4885BCR 3/4885KIT 60/4885 |
| US-20260014129-A1 | MITOCHONDRIAL PYRUVATE METABOLISM INHIBITORS FOR TREATING CHRONIC MYELOID LEUKEMIA | PC, MPC2, PDK1 | ABL1 120/4885BCR 85/4885KIT 2140/4885 |
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | PTK2, ILK, FPR2 | ABL1 1726/4885BCR 283/4885KIT 2806/4885 |
| US-20250090495-A1 | CDC7 Inhibitor Combinational Therapy | CDC7, MCM7, BOD1L1 | ABL1 136/4885BCR 1036/4885KIT 1979/4885 |
| US-11229650-B2 | Inhalable imatinib formulations, manufacture, and uses thereof | ABL1, ALK, IL5 | ABL1 1/4885BCR 197/4885KIT 6/4885 |
| US-12637415-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | GLS, GLUL, GLS2 | ABL1 4003/4885BCR 4175/4885KIT 4349/4885 |
| US-20220241278-A1 | INHALABLE IMATINIB FORMULATION | ABL1, ALK, ABL2 | ABL1 1/4885BCR 69/4885KIT 6/4885 |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | MAP3K1, MAP3K3, MAPK1 | ABL1 417/4885BCR 1479/4885KIT 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.